Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of BMS-247550 [ixabepilone] and Pegylated Liposomal Doxorubicin (Doxil) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane and Phase I Study of Patients With Metastatic Breast Cancer

Next Previous
X
Search
Trial Profile

A Phase I/II Study of BMS-247550 [ixabepilone] and Pegylated Liposomal Doxorubicin (Doxil) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane and Phase I Study of Patients With Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Ixabepilone (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Mar 2016 A protocol amendment was made during phase I trial from a treatment regimen of Schedule A (ixabepilone every 3-4 weeks) to Schedule B (ixabepilone every week). The maximum tolerated dose was determined to be the preceding dose of any dose that resulted in 2 DLT events. Schedule B was carried forward to the phase II trial. The Maximum Tolerated Dose for Schedule B is reported.
    • 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Jan 2008 The expected completion date for this trial is now 1 May 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top